167 related articles for article (PubMed ID: 33015617)
1. Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models.
Inkoom A; Ndemazie N; Affram K; Smith T; Zhu X; Underwood P; Krishnan S; Ofori E; Han B; Trevino J; Agyare E
Int J Pharm X; 2020 Dec; 2():100056. PubMed ID: 33015617
[TBL] [Abstract][Full Text] [Related]
2. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E
BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.
Ndemazie NB; Inkoom A; Ebesoh D; Bulusu R; Frimpong E; Trevino J; Han B; Zhu X; Agyare E
BMC Cancer; 2022 Dec; 22(1):1345. PubMed ID: 36550419
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells.
Affram KO; Smith T; Ofori E; Krishnan S; Underwood P; Trevino JG; Agyare E
J Drug Deliv Sci Technol; 2020 Feb; 55():. PubMed ID: 31903101
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
[TBL] [Abstract][Full Text] [Related]
6. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice.
Kattel K; Mondal G; Lin F; Kumar V; Mahato RI
Mol Pharm; 2017 May; 14(5):1365-1372. PubMed ID: 27798825
[TBL] [Abstract][Full Text] [Related]
8. Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancer.
Frimpong E; Bulusu R; Okoro J; Inkoom A; Ndemazie N; Rogers S; Zhu X; Han B; Agyare E
Eur J Pharm Sci; 2024 May; 196():106754. PubMed ID: 38554983
[TBL] [Abstract][Full Text] [Related]
9. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
[TBL] [Abstract][Full Text] [Related]
10. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
[TBL] [Abstract][Full Text] [Related]
11. Anticancer effect of locally applicable aptamer-conjugated gemcitabine-loaded atelocollagen patch in pancreatic cancer patient-derived xenograft models.
Hong SS; Lee S; Lee SH; Kim S; Kim D; Park H; Lee J; Lee JH; Kang CM
Cancer Sci; 2022 May; 113(5):1752-1762. PubMed ID: 35243724
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antitumor activity of gemcitabine loaded thermosensitive liposomal nanoparticles and mild hyperthermia in pancreatic cancer.
Affram K; Udofot O; Cat A; Agyare E
Int J Adv Res (Indore); 2015 Oct; 3(10):859-874. PubMed ID: 26677454
[TBL] [Abstract][Full Text] [Related]
14. Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer.
Hiroshima Y; Maawy AA; Katz MH; Fleming JB; Bouvet M; Endo I; Hoffman RM
J Surg Oncol; 2015 Mar; 111(3):311-5. PubMed ID: 25394368
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
16.
Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
[TBL] [Abstract][Full Text] [Related]
17. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Kawaguchi K; Igarashi K; Miyake K; Lwin TM; Miyake M; Kiyuna T; Hwang HK; Murakami T; Delong JC; Singh SR; Clary B; Bouvet M; Unno M; Hoffman RM
Tissue Cell; 2018 Jun; 52():124-128. PubMed ID: 29857821
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models.
Kawaguchi K; Miyake K; Zhao M; Kiyuna T; Igarashi K; Miyake M; Higuchi T; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(16):2019-2026. PubMed ID: 29963961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
